Hereditary Breast and Ovarian Cancer Syndrome. Background Information 10% of ovarian cancer is genetic 5% of breast cancer is genetic BRCA 1 and 2.

Slides:



Advertisements
Similar presentations
IUD Safety Research has proven IUDs to be safe and effective Research has proven IUDs to be safe and effective Elements of high quality care: appropriate.
Advertisements

Dysmenorrhea, Menopause, Fibrocystic Breast Disease Ricci, pp ; 101, 150;
Female Reproductive System
1 Female Reproductive Disorders. 2 Problems Related to Menstruation Premenstrual Syndrome Dysmenorrhea Oligomenorrhea Amenorrhea Menorrhagia Metrorrhagia.
2009. WHO IS A SURVIVOR? AN INDIVIDUAL IS A SURVIVOR FROM THE TIME OF THEIR DIAGNOSIS THROUGH THE BALANCE OF THEIR LIFE.
Epidemiology of Gynaecological Cancers. General Overview On global basis cervical cancer is the most common pelvic malignancy in developing countries.
Gynecologic Cancers Presented by: Michael Goodheart, MD Assistant Professor Gynecologic Oncology The University of Iowa Hospitals & Clinics Understanding,
Endometrial Cancer Tseng Jen-Yu 02/05/2007 Tseng Jen-Yu 02/05/2007.
Hereditary Factors in Breast Cancer
Hereditary breast and ovarian cancer Who should be screened and How? Symposium on Cancer Waterloo Inn October 31, 2007 Mala Bahl, MD, MSc.
Hereditary Breast & Ovarian Cancer Syndrome HBOC Tammy McKamie RN MSN OCN Cancer Genetics Educator Clinical Oncology Patient Navigator.
YOLANDA LAWSON M.D., F.A.C.O.G MADEWELL OBGYN ASSOCIATE ATTENDING BAYLOR UNIVERSITY MEDICAL CENTER Women's Health Screening Guidelines.
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
IS HRT SAFE? Rosol Hamid Consultant O&G. NO What is safe? Driving Swimming Crossing the street Cycling Riding a motor bike Parachute jumping Flying.
FEMALE REPRODUCTION.
Post Menopausal Bleeding
Ovarian cancer….. in 15 minutes
Women's Health ISU Student Health Promotions
Passport to Health Preventing and Recognizing Gynecologic Cancers Presented by: Kelly Ward, MD.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
 Not being able to get pregnant  Common causes for females:  Fallopian tube blockage  Ovulation disorders  Polycystic ovary syndrome  endometriosis.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
SUMAYYA EBRAHIM GYNAECOLOGIST PARKLANE CLINIC JOHANNESBURG
FEMALE GENITAL SYSTEM PREMED H&P.
Dr Matt Hewitt Prophylactic Bilateral Salpingoophorectomy.
Ovarian Tumours Max Brinsmead MBBS PhD November 2014.
Fallopian Tube and Ovarian Malignancy Schwartz's Principles of Surgery Chapter 41. Gynecology.
Cancer Cancer is the uncontrolled growth of abnormal cells in the body Cancer occurs when the cells divide too rapidly. Also when cells “forget” to die.
Ovarian Pathology for Undergraduates Max Brinsmead MB BS PhD November 2014.
Ovarian Cancer Research in Allied Health Erin Brewer.
Cancer Screening 101 What All Adults Should Know Donna L. Milavetz, MD, MPH OnSite Care Medical Director.
OVARIAN CANCER RISK FACTORS Studies have found the following risk factors for ovarian cancer:  Family history of cancer: Women who have a mother, daughter,
Ovarian Cancer Risk Reduction Taking oral contraceptives for 5 years can reduce your risk of ovarian cancer by up to 50% Hankinson SE, Colditz GA, Hunter.
Bell Ringer State the functions of the male reproductive system Order the path of the sperm through the following reproductive organs: penis, urethra,
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
Endometrial Cancer By Jessica Hall. Symptoms Unusual vaginal bleeding or discharge Difficult or painful urination Pain during intercourse Pain in the.
Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.
Genetics: For this Generation and the Next
Gynecological Malignancies. Gynecologic malignancies account for 15% of all cancers in women. Gynecologic malignancies account for 15% of all cancers.
PELVIC INFLAMMATORY DISEASE (PID)
Female Reproductive System
Female Anatomy.
Vulvodynia Research Studies: National Institutes of Health.
Dr. Ahmed jasim Ass.Prof. MBChB-DOG-FICMS COSULTANT OF GYN. & OBST.
Better Health. No Hassles. Ovarian Cancer Sokan Hunro, PAC, MPH.
Female Anatomy.
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Describe the symptoms, causes, and treatments of: Female infertility Ovarian Cysts Breast Cancer Human Papillomavirus.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Reproductive Disorders. Web Sites /player/science/health-human-body-sci/
SCREENING IN GYNECOLOGICAL CANCER Taravat Fakheri OB/GYN KUMS.
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
The Elliott Breast Center * Baton Rouge, LA *
M E N O P A U S E King Khalid University Hospital Department of Obstetrics & Gynecology Course 482.
ON THE PILL JANETH SOTO GATEWAY COMMUNITY COLLEGE.
Screening for Ovarian Cancer
AROMATASE INHIBITORS.
Breast Cancer Updates Risks, Genetics, DCIS
Chronic pelvic pain By Dr. Dalya Muthefer.
Male and Female Reproductive Health Concerns
Family Tree Presentation
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Female Sexual Anatomy and Physiology
Genetic Counseling & Testing for Cancer Risk
Gynaecological referrals from primary to secondary care Dr Fozia Malik MRCOG,DFSRH 14/11/2018.
Female Reproductive System
Prophylactic Oophorectomy
Presentation transcript:

Hereditary Breast and Ovarian Cancer Syndrome

Background Information 10% of ovarian cancer is genetic 5% of breast cancer is genetic BRCA 1 and 2

BRCA Incidence is 1 out of in the general population BRCA 1 pos risk of ovarian cancer is 39-46% and risk of breast cancer is 65-75% BRCA 2 pos risk of ovarian cancer is 12-20% and risk of breast cancer is 65-75% BRCA pos ovarian cancer is mainly high grade serous or endometroid

20-25% Chance of BRCA pos PH of both breast and ovarian cancer PH of ovarian cancer and 1 close relative with ovarian cancer or premenopausal breast cancer PH of breast cancer <50 and close relative with ovarian cancer or male breast cancer any age FH of close relative that is BRCA pos

5-10% Chance of BRCA PH breast cancer <40 years PH of high grade serous ovarian cancer any age PH of bilateral breast cancer PH of breast cancer <50 yrs and close relative with breast cancer <50 yrs PH of breast cancer any age and 2 close relatives with breast cancer any age

What to do if BRCA pos? Ca 125 and pelvic ultrasound beginning age Use birth control pills for contraception Prophylactic BSO – Ovarian cancer reduction 90% – Breast cancer reduction 40-70% Prophylactic mastectomy – 90-95% reduction

What to do if BRCA pos? Breast MRI annually at age 25 Tamoxifen – Only helps BRCA 2 with reduction of 60%

Salpingectomy for Prevention of Ovarian Cancer in Low Risk Populations

Should the fallopian tube be removed and leave the ovaries? Concern regarding reduced ovarian function when you remove the tube Preserving the ovaries would benefit woman when it comes to bone health and cardiovascular disease Total salpingectomy is not reversible

Vulvodynia Formerly known as Vestibulitis or Vestibular Adenitis

Clinical Triad Entrance dysparunia Recurrent bouts of vaginitis Chronic UTI episodes or symptoms

Physical Exam Initial inspection to look for dermatologic causes of pain Map tender areas with a Q-tip Speculum exam to look for atrophy or vaginitis Single digit exam to isolate areas of tenderness Bimanual exam to determine if there is cervical, uterine, or adenexal tenderness

Treatment Avoid vulvar irritants Mid potency corticosteroid ointment Topical lidocaine 5% ointment Tricyclic antidepressants Gabapentin Topical estrogen Pelvic floor relaxation